Lassen Therapeutics Announces Presentations on Novel IL-11 Receptor-Blocking Antibody at the American Thoracic Society 2022 Annual Meeting

SAN DIEGO–(BUSINESS WIRE)–Lassen Therapeutics, a biotech company developing breakthrough antibody therapeutics as potential treatments for fibrosis, rare diseases, and oncology, today announced upcoming presentations of new data on its novel IL-11 receptor-blocking antibody at the American Thoracic Society (ATS) Annual Meeting being held in San Francisco, May 13-18, 2022. In addition to the presentation at the ATS Annual Meeting, Lassen will be highlighted as a Fibrosis Featured Company at th
Click here to view original post